Niu-Huang-Shen suppresses hepatocellular carcinoma cell growth and metastasis by regulating Yap1 expression

Hepatocellular carcinoma (HCC) is one of the most common cancers types. Niu-Huang-Shen (NHS), a Chinese medicine, has been reported to exert antipyretic, anti-inflammatory and vasodilatation effects. However, whether NHS has inhibitory effects on HCC cell phenotypes has remained elusive. In the pres...

Full description

Saved in:
Bibliographic Details
Published in:Experimental and therapeutic medicine 2017-12, Vol.14 (6), p.5459-5463
Main Authors: Peng, Yanfang, Zhao, Yingqian, Ye, Taisheng, Zhang, Yabing, Wu, Zhaoyan, Xia, Yukun, Zhang, Yingwen
Format: Article
Language:English
Subjects:
Apoptosis
Cancer therapies
Care and treatment
Cell cycle
Cell growth
Chinese medicine
Development and progression
Genetic aspects
Growth factors
Health aspects
Hepatocellular carcinoma
Kinases
Liver cancer
Medical prognosis
Metastasis
Niu-Huang-Shen
Proteins
Traditional Chinese medicine
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatocellular carcinoma (HCC) is one of the most common cancers types. Niu-Huang-Shen (NHS), a Chinese medicine, has been reported to exert antipyretic, anti-inflammatory and vasodilatation effects. However, whether NHS has inhibitory effects on HCC cell phenotypes has remained elusive. In the present study, Cell Counting Kit-8, colony formation, fluorescence-activated cell sorting and Transwell assays were used to evaluate the effect of NHS on cell proliferation, migration and invasion. The results indicated that NHS suppressed cell proliferation and invasion, inhibited cell apoptosis, and induced cell cycle arrest. In addition, NHS significantly suppressed the mRNA and protein expression of Yes-associated protein (YAP). It was concluded that NHS downregulated YAP expression and inhibited the Hippo signaling pathway as well as HCC cell growth and invasion. NHS may be a novel potential therapeutic for HCC patients.
ISSN:1792-0981
1792-1015
DOI:10.3892/etm.2017.5247